Cannabinoids

(avery) #1

10 R.G. Pertwee


Table 3.Kivalues of cannabinoid receptor antagonists/inverse agonists for the in vitro displacement of
[^3 H]CP55940 from CB 1 -andCB 2 -specific binding sites


Ligand CB 1 CB 2 Reference
Kivalue (nM) Kivalue (nM)

CB 1 -selective antagonists/inverse agonists
NESS 0327 0.00035a 21 a Ruiu et al. 2003
SR141716A 11.8 13,200 Felder et al. 1998
11.8 973 Felder et al. 1995
12.3 702 Showalter et al. 1996
5.6 >1,000 Rinaldi-Carmona et al. 1994
1.98b >1,000b Rinaldi-Carmona et al. 1994
1.8a 514 a Ruiu et al. 2003
AM281 12 b 4,200a Lan et al. 1999a
AM251 (compound 12) 7.49b 2,290a Lan et al. 1999b
LY320135 141 14,900 Felder et al. 1998
CB 2 -selective antagonists/inverse agonists
AM 630 5,152 31.2 Ross et al. 1999a
SR144528 437 0.60 Rinaldi-Carmona et al. 1998
305 b 0.30b Rinaldi-Carmona et al. 1998
>10,000 5.6 Ross et al. 1999a
70 a 0.28a Ruiu et al. 2003
50.3 1.99 Iwamura et al. 2001

See Figs. 10 and 11 for the structures of the compounds listed in this table.
aBinding to mouse brain (CB 1 ) or spleen tissue (CB 2 ).
bBinding to rat cannabinoid receptors on transfected cells or on brain (CB 1 ) or spleen tissue (CB 2 ).
All other data from experiments with human cannabinoid receptor.


(reviewed in Howlett et al. 2002; Pertwee 1997, 1999a). Both assays can be per-
formed with membranes obtained from brain tissue or from cultured cells that
express CB 1 or CB 2 receptors either naturally or after transfection. In addition, the
cyclic AMP assay can be performed with whole cells, including primary cultures of


central neurons, and the [^35 S]GTPγS assay can be used in autoradiography exper-


iments with tissue sections (Breivogel et al. 1997; Selley et al. 1996; Sim et al. 1995).


The cyclic AMP assay is more sensitive than the [^35 S]GTPγS assay. Presumably


this is because modulation of cyclic AMP production takes place further along the


signalling cascade than [^35 S]GTPγS binding so that there is greater signal amplifi-


cation. For the [^35 S]GTPγS assay, it is important to include guanosine diphosphate


(GDP) and sodium chloride at appropriate concentrations (Breivogel et al. 1998;
Selley et al. 1996; Sim et al. 1995). GDP increases the ratio of agonist-stimulated


to basal [^35 S]GTPγS binding (signal-to-noise ratio) but also decreases the abso-


lute levels of both agonist-stimulated and basal [^35 S]GTPγS binding. In addition,


it magnifies the differences in efficacy exhibited in this assay by full and partial
agonists (Savinainen et al. 2001). The signal-to-noise ratio in this bioassay can be
further improved by including an adenosine A 1 receptor antagonist (Savinainen


http://www.allitebooks.com

Free download pdf